PD6-3-5: Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel, and cost-effective versus best supportive care (BSC) in NSCLC

Abstract

The data from these focus groups should be viewed in light that the patients participating were all well enough to do so. Needs of people with more advanced disease (and their carers) may be different. Conclusions: This study contributes to increased understandings of the patient experience, and that of informal carers, to assist in the provision of information for decision making and in supporting patients in coping with NSCLC. These findings will also contribute to understandings of the experiences of NSCLC patients and carers, compared to those with other cancers. Care should be taken in ensuring that people with NSCLC do not "fall through the cracks" of treatment services and are able to find the support they require.

Erlotinib

“…[23,[45][46][47] The models had a time horizon of 2 [28][29][30]32,36,37] or 3 [31,34,35] years, or a lifetime. The models had three health states (progression free, progression and death), with transition probabilities and outcomes derived from pivotal clinical trials of the treatment of advanced NSCLC in patients who had previously received chemotherapy.…”

“…The models had three health states (progression free, progression and death), with transition probabilities and outcomes derived from pivotal clinical trials of the treatment of advanced NSCLC in patients who had previously received chemotherapy. [28][29][30][31][32][33][34][35][36] Where stated, analyses assumed that patients were receiving erlotinib as either second-or third-line treatment, [28,29,31,[33][34][35]37] with the exception of two analyses [32,36] that assumed patients were only receiving second-line treatment. [33] Based on the results of pivotal clinical trials, [23,45,46] 2-3 years is essentially the lifetime of the patient cohorts.…”

“…cost per life-year [LY] gained) [28,30,31,35,36] and/or cost utility (i.e. cost per life-year [LY] gained) [28,30,31,35,36] and/or cost utility (i.e.…”

“…the effect of adverse events and the disutility difference between oral and intravenous therapy), leading to between-group differences in QALYs gained. [28][29][30][31][32][33][34][35][36][37] Country-specific direct medical costs associated with treatment of NSCLC (e.g. [21] The analyses were conducted from a healthcare payer perspective in numerous North American, European and Asian countries.…”

“…[28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] The comparators in the analyses include docetaxel, pemetrexed and/or best supportive care. [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] The comparators in the analyses include docetaxel, pemetrexed and/or best supportive care.…”